Ordenar

Buscar

01/04/2026 Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis
Cortés-Vicente, E, Guerrero, A, Díaz, C, Martínez, E, Toja-Camba, FJ, Abad, MR, Serra, JM, Trillo, JL, Machín, CM, Gil, A. Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis. ADVANCES IN THERAPY. 2026; 43(4)DOI:10.1007/s12325-026-03490-x. PMID:41591648. IF:4.000(Q1/3D).
01/04/2026 Clinical Heterogeneity and Candidate Biomarkers in POLG-Related Mitochondrial Disease
Bermejo-Guerrero, L, Restrepo-Vera, JL, Martin-Jimenez, P, Navarro-Riquelme, M, Garrido-Moraga, R, Ochoa, LE, González-Quintana, A, Hernandez-Lain, A, Castillo-Villalba, J, Morís, G, Muelas, N, García-Arumí, E, González, V, Martínez-Sáez, E, Vesperinas, A, Llansó, L, Juntas-Morales, R, Paradas, C, Kapetanovic, S, Blázquez, A, Martí, R, Arenas, J, Martín, MA, Domínguez-González, C. Clinical Heterogeneity and Candidate Biomarkers in POLG-Related Mitochondrial Disease. Neurology-Genetics. 2026; 12(2)DOI:10.1212/NXG.0000000000200365. PMID:41822038. IF:3.700(Q1/3D).
01/04/2026 Myasthenia gravis in Spain: A survey of specialized neurologists to uncover unmet needs
Cortés-Vicente, E, Casasnovas, C, Juntas, R, Sevilla, T, Pardo, J, de Rivera, FR, Sola, AG. Myasthenia gravis in Spain: A survey of specialized neurologists to uncover unmet needs. NEUROLOGIA. 2026; 41(3)DOI:10.1016/j.nrl.2025.501912. PMID:. IF:3.100(Q2/4D).
01/04/2026 Fulzerasib plus cetuximab in first-line KRASG12C-mutated nonsmall-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
Gregorc, V, Majem, M, Lo Russo, G, Maio, M, Salvagni, S, Gutiérrez-Calderon, V, Gonzalez-Cao, M, Contreras, SS, Koumarianou, A, Bearz, A, Bernabé-Caro, R, Viteri, S, de Sanmamed, MF, Zagouri, F, Bueno, TM, Lazzari, C, Martínez-Recio, S, Giménez-Capitán, A, Zhang, Y, Shan, Y, Zhu, HQ, Zhao, CQ, Shen, HG, Wang, Y, Rosell, R. Fulzerasib plus cetuximab in first-line KRASG12C-mutated nonsmall-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial. LANCET ONCOLOGY. 2026; 27(4)DOI:10.1016/S1470-2045(25)00764-8. PMID:41926959. IF:35.900(Q1/1D).